Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.41 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.41 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.41 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.41 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.41 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.41 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.41 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.41 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167328 | 0.84 | CTSK (0.56) | CTSKHTR6KCNH2NTSR1POLB | |
| SCHEMBL7175172 | 0.80 | CTSK (0.53) | CTSKHTR6KCNH2NTSR1POLB | |
| SCHEMBL7163876 | 0.80 | HTR6 (0.43) | CTSKHTR6KCNH2NTSR1POLB | |
| SCHEMBL7530060 | 0.79 | CTSK (0.69) | CTSKMMP1ADAM17KCNA5CTSL | |
| SCHEMBL7164468 | 0.78 | CTSK (0.52) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7561995 | 0.77 | MMP1 (0.49) | CTSKMMP1ADAM17CTSLCTSS | |
| SCHEMBL7524135 | 0.77 | MMP1 (0.47) | CTSKNTSR1POLBMMP1ADAM17 | |
| SCHEMBL7468069 | 0.73 | PPARG (0.64) | POLBPPARG | |
| SCHEMBL7169622 | 0.72 | CTSK (0.45) | CTSKHTR6KCNH2NTSR1POLB | |
| SCHEMBL7563529 | 0.71 | CTSL (0.52) | CTSKMMP1ADAM17CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885HTR6 3754/4885KCNH2 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.